Jeffery Kelly is the Lita Annenberg Hazen Professor of Chemistry at the Scripps Research Institute. He was born in New York, earned a B.S. & Ph.D. in chemistry, carried out post-doctoral training at The Rockefeller University in Biochemistry before starting his career at Texas A&M and moving to Scripps in 1997. The central theme of his research is to understand the chemistry and biology influencing the competition between protein folding, misfolding, and aggregation—the latter processes being associated with a spectrum of human degenerative diseases. Mechanistic knowledge gained from these studies is used to conceive of new therapeutic strategies-his current focus. Kelly’s lab discovered the blockbuster drug tafamidis, the first drug that slowed the progression of a human amyloid disease.
Further Activities to have a look at